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Tc1 mouse model of Down syndrome (DS) is functionally trisomic for ∼120 human chromosome 21 (HSA21)
classical protein-coding genes. Tc1 mice display features relevant to the DS phenotype, including abnormal-
ities in learning and memory and synaptic plasticity. To determine the molecular basis for the phenotypic fea-
tures, the levels of 90 phosphorylation-specific and phosphorylation-independent proteins were measured by
Reverse Phase Protein Arrays in hippocampus and cortex, and 64 in cerebellum, of Tc1 mice and littermate
controls. Abnormal levels of proteins involved in MAP kinase, mTOR, GSK3B and neuregulin signaling were
identified in trisomic mice. In addition, altered correlations among the levels of N-methyl-D-aspartate (NMDA)
receptor subunits and the HSA21 proteins amyloid beta (A4) precursor protein (APP) and TIAM1, and between
immediate early gene (IEG) proteins and the HSA21 protein superoxide dismutase-1 (SOD1) were found in the
hippocampus of Tc1 mice, suggesting altered stoichiometry among these sets of functionally interacting pro-
teins. Protein abnormalities in Tc1 mice were compared with the results of a similar analysis of Ts65Dn mice,
a DS mouse model that is trisomic for orthologs of 50 genes trisomic in the Tc1 plus an additional 38 HSA21
orthologs. While there are similarities, abnormalities unique to the Tc1 include increased levels of the S100B
calcium-binding protein, mTOR proteins RAPTOR and P70S6, the AMP-kinase catalytic subunit AMPKA, the
IEG proteins FBJ murine osteosarcoma viral oncogene homolog (CFOS) and activity-regulated cytoskeleton-
associated protein (ARC), and the neuregulin 1 receptor ERBB4. These data identify novel perturbations, rele-
vant to neurological function and to some seen in Alzheimer’s disease, that may occur in the DS brain, po-
tentially contributing to phenotypic features and influencing drug responses.
INTRODUCTION
Down syndrome (DS) is caused by an extra copy of the long
arm of human chromosome 21 (HSA21). The incidence of
DS in the USA and Europe is 1/750 and 1/1000 live
births, respectively, making DS the most common genetic
cause of intellectual disability (ID) (1,2). Individuals with
DS have impairments in hippocampal-based learning, execu-
tive function and language skills and, while ID can be mild,
it is reflected in an average IQ of 40–50 (3–5). At birth, the
brain in DS is described as grossly normal, but postnatal de-
velopment slows and the adult brain in DS is characterized
by decreased hippocampal and cerebellar volumes, decreased
neuronal densities and altered dendritic spine morphologies
(6,7). DS is also associated with relatively high incidences
of autism (10%) and seizures (10%), plus early develop-
ment of the neuropathology of Alzheimer’s disease (AD)
and an AD-like dementia (7,8).
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The DS phenotype is assumed to be the result of over ex-
pression, due to increased copy number, of subsets of
HSA21 genes that lack mechanisms for dosage compensation.
HSA21, by recent genomic sequence annotation, encodes
550 genes (9). Of these, 161 are annotated as protein
coding in SwissProt and NCBI RefSeq protein databases and
5 are annotated as microRNAs. Creating an ideal mouse
model of DS, i.e. one that is trisomic for all HSA21 genes,
is a challenge because orthologs of these genes are dispersed
among regions of three mouse chromosomes. The five micro-
RNA genes and 101 RefSeq protein-coding (RefSeqP) genes
map to the telomeric region of mouse chromosome 16, and 19
and 38 RefSeqP genes map to internal segments of mouse chro-
mosomes 17 and 10, respectively (9). Four HSA21 RefSeqP
genes (POTED, TCP10L, DSCR4 and PLAC) are not conserved
in the mouse genome.
As a solution to the challenge of creating a mouse trisomic
for all three chromosomal regions orthologous to HSA21, the
Tc1 DS model was constructed to contain a freely segregating
human HSA21 (10). Thus, Tc1 mice carry the human ortho-
logs, including the human-specific genes, in a background of
a complete set of mouse chromosomes. Some deletions and
rearrangements affecting 40 HSA21 genes occurred during
construction of the model, and, as a result, Tc1 mice are func-
tionally trisomic for 121 of the 161 RefSeq protein coding
genes (10,11; and F.K.Wiseman, unpublished data). They
show a number of DS-relevant phenotypic features, including
short-term memory deficits and abnormalities in long-term po-
tentiation (LTP) (10,12). Little is known about the molecular
abnormalities that underlie these and other features described
for the Tc1. Here, we describe patterns in abnormalities of 90
proteins, HSA21 and non-HSA21, in cortex and hippocampus,
and 64 in cerebellum. Abnormalities include altered levels of
proteins and altered correlations among levels of functionally
related proteins. Furthermore, abnormalities in Tc1 mice differ
considerably from those previously reported in the popular
Ts65Dn mouse model of DS. These data suggest that the mo-
lecular basis of the phenotype of full trisomy 21, i.e. in indivi-
duals with DS, will differ from those of both the Tc1 and the
Ts65Dn. This conclusion has implications for development of
pharmacotherapies for cognitive deficits in DS.
RESULTS
HSA21 and orthologous protein expression
Table 1 lists proteins that were measured, with their levels in
the cortex, hippocampus and cerebellum in Tc1 mice relative
to controls. All antibodies to HSA21-encoded proteins were
verified to cross-react with both human and mouse proteins;
therefore, levels in Tc1 represent expression from two
copies of the mouse gene plus that from the orthologous
HSA21 gene. Of the 16 HSA21 proteins measured, genes for
11 are intact in the Tc1 chromosome and therefore these
genes are functionally trisomic (10,11; F.K.Wiseman, unpub-
lished data). Of these, only TIAM1, SOD1, DYRK1A and
S100B proteins show the elevated levels expected from
trisomy, compared with controls (Table 1; Fig. 1, for
TIAM1 and S100B that were measured by western blots). Al-
ternative splicing of TIAM1 transcripts produces five protein
isoforms, migrating as a 200 kDa doublet, a 150 kDa
doublet and a 70 kDa form (13). In addition, proteolytic pro-
cessing produces a 75 kDa product (14). In hippocampus, all
four bands are increased by a relatively uniform 41–75%,
while in the cortex, the levels of increase vary from 21 to
85%. SOD1 levels average a 50% increase, but the levels in
the hippocampus are highest at 75% and cerebellum lowest
at 36%. DYRK1A levels range from a 57% increase in the
cortex to 95% in cerebellum, consistent with a previous
report (15). Finally, S100B levels were increased by 99 and
112% in the cortex and hippocampus, respectively. Although
S100B has been reported to be duplicated in the Tc1 HSA21,
protein levels remain only marginally higher than those seen
for SOD1 and DYRK1A. In contrast to these four, proteins
encoded by the remaining seven trisomic genes, such as CCT8,
CHAF1B, ETS2, RRP1, FTCD, ADARB1 and PRMT2, show
no differences in levels from controls (data not shown).
The 11 trisomic genes are widely distributed within HSA21;
CCT8, TIAM1, SOD1, CHAF1B and ETS2 map within an in-
ternal segment spanning 15 Mb on HSA21, and the remain-
ing four map within a 2 Mb telomeric segment of HSA21
(9). Notably, the genes encoding S100B, which is overex-
pressed, and PRMT2, which is not overexpressed, are adjacent,
organized 5′ to 5′, and separated by only 30 kb immediately
telomere proximal on HSA21.
Three genes, DONSON, ITSN1 and RCAN1, are within the
large HSA21 deletion that spans C21orf45 through RUNX1
(10,11; Supplementary Material, Table S6). As expected,
DONSON and RCAN1 protein expression levels do not
differ from controls. Interestingly, however, the levels of
ITSN1 are elevated, in the cortex, hippocampus and cerebel-
lum, to the levels comparable with those of proteins encoded
by the trisomic genes, TIAM1, SOD1 and DYRK1A. There
are no known mechanisms for regulation of ITSN1 expression
by the genes trisomic in the Tc1. However, ITSN1 was recent-
ly shown to be one of the genes regulated by the neuregulin
1 receptor ERBB4 (16) and elevated ITSN1 may be caused
by overexpression of ERBB4 in the Tc1 (see below). Alterna-
tively, ITSN1 interacts with TIAM1 (17); it is possible that
overexpression of TIAM1 indirectly drives increased ITSN1
expression, as has been observed in other cases of functionally
interacting proteins (18). Finally, the APP gene is not deleted
from the HSA21 chromosome, but rearrangements within the
coding region inhibit transcription (15), and hence no human
APP protein is produced and total APP levels are not elevated.
Similarly, the TRPM2 gene, in distal HSA21, is also rear-
ranged, and TRPM2 protein is not elevated.
Non-HSA21 ortholog protein expression
The goal of the protein measurements was to assess potential
perturbations in pathways known or predicted to be relevant to
learning/memory and other neurological abnormalities seen in
DS or mouse models of DS. For direct comparison with prior
studies, proteins chosen for analysis include those previously
measured in the Ts65Dn (13), among them components of
the MAP kinase pathway, subunits of the NMDA receptor
complex, and proteins involved in nerve growth factor signal-
ing, apoptotic responses and dendritic spine formation. We
also measured proteins relevant to the pathology of AD, e.g.
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Tau and a-Synuclein, because AD is common in DS. While
the APP gene, which is an obvious candidate for AD in DS,
is not overexpressed in the Tc1, and neurodegeneration has
not been reported, additional HSA21 genes that are uniquely
trisomic in the Tc1 could also contribute to the development
or progression of the AD pathology or cognitive decline that
is seen in the DS brain. Lastly, we measured the products of
several immediate early genes (IEGs) and additional compo-
nents of the mTOR signaling pathway because altered expres-
sion of these at the mRNA or protein level has been reported
in the Tc1, the Ts65Dn or another DS mouse model, the
Ts1Cje (15,19,20).
Because Reverse Phase Protein Arrays (RPAs) require
highly specific antibodies, not all proteins of interest could
be measured. This was particularly the case for many anti-
bodies raised against human proteins, where cross reactivity
with orthologous mouse proteins was either undetectable or
accompanied by high background or non-specific bands.
Table 1 lists the 72 and 77 non-HSA21 proteins that were mea-
sured in the cortex and hippocampus (one by western blot), re-
spectively, and the subset of 52 that were measured in the
cerebellum. In some cases, pairs of antibodies directed at
phosphorylation-dependent and phosphorylation-independent
forms of the same protein were used. In total, 21 non-HSA21 pro-
teins (30%) were significantly altered in one or more brain
regions, and eight of these were altered in all brain regions
analyzed.
Phosphorylated forms of 17 proteins that are components of
signaling pathways were measured. Only three were altered.
Levels of pERK1/2 and pELK1 each were robustly elevated,
by 50% or more, in all three brain regions. Increases were
highest, at 94 and 76%, respectively, in the cerebellum.
Table 1. Tc1 protein expression
Protein CR HP CB nc: CR, HP, CB #nc: CR, HP
Hsa21 proteins
TIAM1_200 38%∗∗∗ 41%∗∗∗ ND APP, CCT8, DONSON, CHAF1B, ETS2, TRPM2,
ADARB1, FTCD, PRMT2
RRP1, RCAN1
TIAM1_150 21%∗ 45%∗∗∗ ND
TIAM1_75 44%∗∗ 51%∗∗ ND
TIAM1_70 85%∗∗∗ 70%∗∗ ND
SOD1 43%∗∗∗ 75%∗∗∗ 36%∗∗∗
ITSN1 30%∗∗∗ 35%∗∗∗ 52%∗∗∗
DYRK1A 57%∗∗∗ 67%∗∗∗ 95%∗∗∗
S100B 99%∗∗∗ 112%∗∗∗ ND
Signaling proteins, phosphorylation dependent forms
pERK1/2
(Tyr204)
52%∗∗∗ 73%∗∗∗ 94%∗∗∗ pMEK1/2(Ser 217/221), pBRAF(Thr401),
pRSK(Ser380), pAKT(Ser473), pCREB(Ser133),
pJNK(Thr183/Tyr185), pCAMKIIA/B(Thr286),
pGSK3B(Ser9), pPKCA/B(Thr638/641), pPKCG
(Thr514), pMTOR(Ser2448), pP70S6(Thr389)
pS6(Ser240/244), pEIFB4(Ser422)
pELK1(Ser383) 52%∗∗∗ 50%∗∗∗ 76%∗∗∗
pGSK3B(Tyr216) 12%∗ nc ND
Signaling proteins, phosphorylation independent forms
BRAF 32%∗∗∗ 45%∗∗∗ 61%∗∗∗ ERK1/2, MEK1/2, RSK, CREB, AKT, JNK, CAMKII,
PKCA, P35/25, CDK5, MTOR
S6
GSK3B 21%∗∗∗ 24%∗∗∗ 35%∗∗∗
P70S6 19%∗∗ 17%∗∗∗ ND
AMPKA nc 13%∗ ND
RAPTOR nc 12%∗∗ ND
Apoptosis related
BAD 28%∗ nc nc BCL2, CASP3, pCASP9(Ser196)
BAX nc 214%∗∗∗ nc
Receptors
ERBB4 11%∗∗∗∗ 19%∗∗∗ ND TRKA, NR1, pNR1(Ser889), NR2A,
pNR2A(Tyr1246), NR2B, pNR2B(Tyr1336), GluR3,
GluR4, pGluR2(Tyr876)
RAGE
Immediate Early Genes
cFOS nc 15%∗ ND EGR1
pCFOS nc 17%∗ ND
ARC nc 14%∗ ND
Miscellaneous
pNUMB(Ser276) 28%∗∗∗ nc nc NUMB, pGJA1(Ser368), SHH, SYP, CAT, GAD2,
CTNNB1
Ubiquitin, PSD95, pTau(Thr212),
Histone H3(AcK9), Histone
H3(AcK18), Histone H3(DMeK4),
TH, IL1B
GFAP 29%∗∗∗ nc nc
BDNF 29%∗∗∗ nc nc
Tau 27%∗∗∗ 29%∗∗∗ ND
A-Synuclein 20%∗ nc ND
nNOS 13%∗∗∗ 19%∗∗ ND
PP2A ND 13%∗ ND
Levels are provided as averages for Tc1 relative to 100% in control mice.
CR, cortex; HP, hippocampus; CB, cerebellum. ND, not measured. nc, not changed in Tc1 versus controls. #nc: not changed in the cortex or hippocampus and not
measured in cerebellum. TIAM1 isoforms, S100B and RAGE were measured by western blot and significant differences were determined using the unpaired
Student t-test: ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001. All other proteins were measured by RPA; significant differences using Bonferroni correction: ∗P, 0.0005;
∗∗P, 0.0001; ∗∗∗P , 0.00001. nNOS, neuronal nitric oxide synthase.
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Phosphorylation of other components of the classical MAP
kinase pathway upstream of ERK, among them BRAF and
MEK, were not altered, nor were phosphorylation levels of
the downstream kinase, RSK, or the transcription factor
CREB. No changes in phosphorylated levels of components
of the mTOR pathway were seen, while pGSK3B-Tyr216,
but not GSK3B-Ser9, was increased in the cortex. Other phos-
phorylation levels stable to the effects of the Tc1 trisomy were
those of AKT, CAMKII, JNK and PKC.
Phosphorylation-independent levels of 17 signaling pathway
components were measured. Elevated in all three brain regions
were GSK3B and one component of the MAPK pathway,
BRAF. Although the levels of mTOR remained normal,
several proteins involved in mTOR signaling were altered sig-
nificantly: P70S6 was elevated in the cortex and hippocampus,
and RAPTOR and AMPKA in the hippocampus. Although,
with the exception of pGSK3B-Tyr216, phosphorylated levels
of these proteins were either not increased or not measured,
these data still suggest altered proportions of active versus in-
active forms of components of several signaling pathways.
Modest decreases of apoptosis-related proteins BAD and
BAX were found in the cortex and hippocampus, respectively.
Additional modest decreases were found in the cortex for
phosphorylated NUMB, a protein that functions with HSA21
protein ITSN1 in regulation of dendritic spine morphology
(21), and for BDNF and the glial-specific protein, GFAP.
Among 12 neurologically relevant receptors, no alterations
were seen in either total or phosphorylated forms of TRKA,
or subunits of the NMDA or AMPA receptors. In addition,
although levels of the HSA21 protein S100B were significant-
ly elevated, levels of its receptor, RAGE, were not. However,
levels of ERBB4, the major receptor in brain for neuregulin 1
(NRG1)(22), were elevated in both the cortex and hippocam-
pus. Other proteins of relevance to AD include significant
increases in Tau, but not phosphorylated Tau, and neuronal
NOS in the cortex and hippocampus, and a-Synuclein in the
cortex. Finally, the IEG proteins, ARC, cFOS and phospho-cFOS,
but not EGR1, were elevated specifically in the hippocampus.
Individual variation
Because the HSA21 chromosome segregates freely, the Tc1
mice are mosaics (10). Thus, the percentage of cells carrying
the HSA21 can vary among tissues and will differ among
mice. Without direct measurement, the level of mosaicism is
unknown. The Tc1 mice, in addition, are not maintained on
an inbred background and individuals will have a combination
of 0, 1 or 2 alleles from C57BL/6J and 129/S8, plus the human
Figure 1. TIAM1 and S100B are overexpressed in Tc1 mice. Expression levels of HSA21 proteins TIAM1 and S100B, and the S100B receptor, RAGE, were
examined by westerns blots. Representative gels are shown for (A) cortex, (C) hippocampus. For TIAM1, gels were 8% acrylamide to separate the four bands
that range from 70 to 200 kDa; for S100B (12 kDa) and RAGE (46 kDa), gels were 12% acrylamide. Representative actin signals, used for normalization, are
also shown. C, euploid control; T, trisomic Tc1. (B and D) Results of quantitation from two to three replicate gels as in (A) and (C). For comparison, euploid
control values were set to 100%. The unpaired Student t-test was used to calculate the mean genotype differences; bars indicate standard error of the mean;
∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001.
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allele. Among Tc1 mice, therefore, variations in protein levels
may result from both the level of mosaicism and allelic vari-
ation, while only the latter contributes to variation among con-
trols. Previous work with the Ts65Dn mouse model of DS has
shown variability in protein and phosphorylation levels among
individuals in the groups of trisomic mice and littermate con-
trols (13, 23), and indeed patterns in such variability were used
to predict variability in locomotor response to treatment with
the NMDA receptor antagonist, MK-801 (24). We therefore
investigated individual variation in the Tc1 mice. Data for
several proteins are shown in Table 2. It is noteworthy, first,
that even when mean genotype levels of a protein are
greater in Tc1 mice than in controls, the lowest levels in triso-
mic mice are close to or overlapping with the highest levels in
control mice. Secondly, for these same proteins, variation
among individual Tc1 mice is greater than among controls.
For example, in the cortex of control mice, levels of SOD1
range from 0.11 to 0.15, i.e. 1.3-fold, while in Tc1, they
range from 0.14 to 0.27, almost 2-fold. Similar levels of vari-
ation are seen in the three brain regions for DYRK1A. A
simple interpretation is that these levels reflect the proportion
of cells carrying the HSA21 in the respective regions of indi-
vidual mice. However, the levels of phosphorylated ELK1, a
non-HSA21 protein, cannot be directly a result of mosaicism,
and in the cortex, pELK1 levels vary from 0.20 to 0.32
(1.6-fold) and in trisomic mice, from 0.26 to 0.64 (2.5-fold).
In the cerebellum, pELK1 levels vary from 0.24 to 0.43
(1.8-fold) in controls, and in trisomic mice from 0.3 to 1.08
(3.5-fold). Thirdly, for proteins that do not differ in mean
levels between trisomic mice and controls, the range of
levels among individuals typically is similar in Tc1 mice
and controls. For example, APP in the hippocampus varies
from 0.35 to 0.46 in controls and 0.36 to 0.45 in trisomic
mice, and ARC in the cortex varies from 0.12 to 0.15 and
0.12 to 0.16 in controls and trisomics, respectively. Thus, ele-
vated expression, whether directly or indirectly caused by
trisomy, appears to result in a greater range of variability in
expression among trisomic individuals. One exception to this
observation is seen with the HSA21 protein RCAN1.
RCAN1 is within the large HSA21 deletion and therefore is
not trisomic in Tc1. Consistent with this, the mean levels of
RCAN1 are not different between Tc1 and control genotypes.
However, in both the cortex and hippocampus, there is again
much greater variation in RCAN1 levels in Tc1 than in con-
trols. Scatter plots in Figure 2 illustrate this in comparison
with the levels for APP.
The within-genotype inter-individual variations are not ne-
cessarily random but rather show patterns among individuals.
Bar graphs in Figure 3A–C illustrate this for expression of
three HSA21 proteins in individual mice. Within a brain
region, patterns of DYRK1A and ITSN1 are highly similar.
For example, in the cortex, mice T4, T5 and T2 have the
highest levels of both proteins while mice T1, T6 and T7
have the lowest. In contrast, in the hippocampus, the levels
of DYRK1A and ITSN1 are highest in T5 and T2 but
among the lowest in T4. SOD1 shows a different pattern,
where in the cortex, mice T1 and T7 are highest and T2 and
T5 are lowest. Therefore, factors in addition to or other than
mosaicism are driving trisomic gene overexpression.
To extend this analysis to non-HSA21 proteins, Figure 3D–F
shows bar graphs for pERK, pELK1 and GSK3B. Not only are
patterns of Tc1 variation clearly similar within and specific to
each brain region, but these patterns are also similar to those of
DYRK1A and ITSN1 in the same brain regions (Fig. 3A and
B). A different scenario is presented by levels of proteins
encoded by the IEGs, cFOS, ARC and phosphorylated-cFOS
(Fig. 4). In the hippocampus where mean values are elevated
in Tc1 compared with controls, the patterns of inter-individual
variation are similar, e.g. mice T1 and T3 show the highest
levels, while T5–T7 are the lowest. However, in the cortex,
where protein levels in Tc1 consistently overlap with controls,
patterns among Tc1 mice are not similar to each other
(compare patterns in ARC with cFOS).
Correlations among protein levels
The patterns shown in Figures 3 and 4 indicate relationships
among the levels of these sets of functionally interacting pro-
teins. We therefore investigated correlations between levels of
all pairs of proteins in each genotype in each brain region.
Using criteria of r . 0.82 and P , 0.05 (Spearman correlation
analysis), 200 pairwise correlations were significant in the
Table 2. Range of expression levels for selected proteins
Protein Cortex Hippocampus Cerebellum
Control Tc1 Control Tc1 Control Tc1
APP 0.41–0.54 0.41–0.48 0.35–0.46 0.36–0.45 0.39–0.47 0.37–0.45
SOD1 0.11–0.15 0.14–0.27 0.1–0.12 0.16–0.23 0.11–0.2 0.15–0.23
ITSN1 0.38–0.48 0.45–0.85 0.32–0.45 0.44–0.67 0.39–0.58 0.5–1.18
DYRK1A 0.19–0.26 0.26–0.54 0.16–0.25 0.26–0.46 0.21–0.36 0.31–0.99
pERK1/2 0.34–0.53 0.44–1.23 0.24–0.45 0.46–1.01 0.36–0.7 0.56–1.9
pELK1 0.20–0.32 0.26–0.64 0.19–0.27 0.28–0.47 0.24–0.43 0.3–1.08
GSK3B 0.99–1.23 1.14–1.84 0.83–1.19 1.1–1.5 0.91–1.25 1.09–2.22
BRAF 0.32–0.41 0.32–0.76 0.27–0.42 0.38–0.71 0.39–0.61 0.47–1.4
MTOR 0.39–0.43 0.37–0.42 0.31–0.37 0.31–0.36 0.34–0.39 0.33–0.37
ERBB4 0.15–0.18 0.16–0.22 0.29–0.38 0.32–0.51 ND ND
ARC 0.12–0.15 0.12–0.16 0.36–0.46 0.37–0.59 ND ND
pCFOS 0.19–0.26 0.18–0.29 0.17–0.23 0.17–0.36 ND ND
ND, not measured.
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hippocampus, 125 in the cortex and 100 in the cerebellum
(Supplementary Material, Table S3). After manual review of
scatter plots to eliminate correlations with artifactual signifi-
cance, we generated networks to illustrate correlations involv-
ing proteins with known functional associations. In Figure 5,
networks of correlations among proteins from the MAP
kinase cascade are shown. Notable are correlations among
pERK, BRAF and the HSA21 proteins DYRK1A and ITSN1
that are conserved in the hippocampus and cortex in both
control and Tc1 mice (Fig. 5a and b). Each of these four pro-
teins are increased in the Tc1 but this has not altered correla-
tions, with the exception of a loss of correlation between
ITSN1 and DYRK1A in the hippocampus. In the hippocampus
also, additional correlations are seen involving pBRAF, pRSK,
pMEK, CREB and pCREB (Fig. 5C). Levels of none of these
are altered in the Tc1; however, correlations are seen only in
control mice and, with the exception of pRSK-CREB, are
absent in Tc1. Given the observations of impaired learning
and memory in the Tc1 mice, and the importance of hippo-
campal function and the MAP kinase pathway in learning
and memory (25), perturbed stoichiometry among pathway
components presents one possible molecular feature under-
lying the deficits.
Figure 6A shows a network containing NMDA receptor
subunits with similarly significant correlations. Again in the
hippocampus, while seven pairwise correlations among NMDA
receptor subunits and their phosphorylated forms are present
in both controls and the Tc1, three correlations are lost in
the Tc1. Notable also in Tc1 mice is the loss of correlations
between the HSA21 protein APP and four NMDA receptor
subunits. This is surprising because the levels of APP are
not altered in the Tc1. However, also notable in Figure 6A
are the Tc1-specific, negative correlations between NMDA re-
ceptor subunits and isoforms of TIAM1, a guanine nucleotide
exchange factor with specificity for RAC (26). All isoforms of
TIAM1 are elevated in the Tc1 (Fig. 1A, Table 1), but the
direct correlations with NMDAR subunits involve only the
smallest isoform, a 70 kDa protein, and the product of
caspase-3 cleavage, the 75 kDa protein. The functional conse-
quences of the large TIAM1 isoforms have not been distin-
guished, but caspase cleavage abolishes TIAM1 activity
(14). Both TIAM1 and APP interact directly with NMDA re-
ceptor subunits, TIAM1, in regulation of dendritic spine
morphology (27,28) and APP, to facilitate cell surface expres-
sion of the NMDA receptor (29). Therefore, overexpression of
TIAM1 may alter the stoichiometry of NDMA receptor inter-
actions, either in static or dynamic conditions, and contribute
to the losses of normal correlations both between APP and
NMDAR subunits and among NMDAR subunits. These
altered correlations may contribute to perturbed NMDAR ac-
tivity (23), as well as altered RAC activity, and abnormalities
in LTP in the Tc1 mice. In Figure 6B, a network involving iso-
forms of TIAM1, GSK3B, plus the HSA21 proteins RCAN1
and DYRK1A, are shown. These associations largely have
not been explored experimentally.
A third example of correlation networks is shown in
Figure 7 and involves the IEG proteins, EGR1, ARC and
CFOS. In the hippocampus (Fig. 7A), correlations among
IEG proteins are present in controls and Tc1 mice. The
levels of Tau and nNOS are also correlated in both genotypes.
Notably, the levels of all except EGR1 are elevated in Tc1
mice. Additional correlations specific to the Tc1 include nega-
tive correlations between SOD1, Tau and nNOS, and positive
correlations between Tau and nNOS and the IEG proteins.
Figure 7B shows that IEG protein correlations are quite differ-
ent in the cortex. While correlations among IEG proteins and
with nNOS are present in controls, they are lost in Tc1 mice.
There are also control-specific correlations between IEG pro-
teins and a-Synuclein and the neuregulin receptor ERBB4.
We suggest that losses in correlated levels of component
proteins may contribute to failed responses to stimuli and
underlie impaired or slowed learning responses that also
require MAP kinase signaling, NMDA receptor activity, and/
or IEG responses to stimulation.
DISCUSSION
We have measured levels of 93 proteins in the hippocampus,
88 in the cortex and 64 in the cerebellum. Twenty-six proteins,
HSA21 and non-HSA21, phosphorylated and phosphorylation-
independent, were altered in expression level in at least one
brain region. Thirteen proteins were increased in both the
Figure 2. Individual variation in levels of RCAN1 and APP. Scatter plots
show that RCAN1 levels in Tc1 mice are more variable than in euploid con-
trols. APP levels are shown for comparison. Nether RCAN1 nor APP are
expressed from the Tc1 HSA21 chromosome and neither shows an average
increase in Tc1 mice.
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Figure 3. Variation in protein expression levels. Levels of six proteins determined by RPA are shown in individual euploid controls (white bars) and Tc1 (black bars), in the cortex, hippocampus and
cerebellum. Average levels of all six proteins in Tc1 relative to controls are given in Table 1. (A and C) DYRK1A and SOD1 are trisomic in Tc1 mice; (B) ITSN1 is deleted in the Tc1 chromosome
and therefore functionally disomic; (D, E and F) Levels of non-HSA21 signaling proteins, pERK1/2, pELK and GSK3B.
H
u
m
a
n
M
o
lecu
la
r
G
en
etics,
2
0
1
3
,
V
o
l.
2
2
,
N
o
.
9
1
7
1
5
hippocampus and cortex of Tc1 mice compared with controls.
In the hippocampus, an additional six were increased and one
decreased, and in the cortex, an additional two were increased
and four decreased. In the cerebellum, only seven proteins
were altered, all increased, but this does not imply cerebellum
is more stable to the effects of trisomy because 15 proteins
whose levels were changed in the Tc1 cortex or hippocampus
were not measured in cerebellum. Altered protein levels in-
clude components of MAP kinase, GSK3B and MTOR signal-
ing, IEGs, the ERBB4 neuregulin receptor, Tau, a-Synuclein
and nNOS. Proteins resistant to trisomy include NMDA recep-
tor subunits and most phosphorylated forms of signaling
pathway components.
Prior studies of Tc1 mice have included gene expression
data, although age of mice and/or cell types used differed.
RNA expression levels of 9 of the 11 trisomic HSA21 genes
tested here were reported in Tc1 E14.5 day embryos (10). In
the absence of translational regulatory effects, corresponding
protein levels would then also be elevated. However, only
the levels of TIAM1, SOD1, DYRK1A and S100B are ele-
vated here, while those for CCT8, CHAF1B, ETS2, FTCD
and PRMT2 are not different from controls. The failure to
observe a 50% increase in expression expected from gene
dosage is not uncommon in DS systems. While numerous
microarray and large-scale quantitative reverse transcription
polymerase chain reaction (RT–PCR) studies overall have
supported gene-dosage effects, they have also invariably
reported cell line-, tissue-, age- and gene-specific departures
from it. These results have been summarized in (30). Further-
more, discrepancies between mRNA and protein levels are in-
creasingly being documented (31), and have been reported
specifically in aneuploidy (32). Given the cross-reactivity of
the antibodies used, we cannot determine whether the human
transcripts are inefficiently translated, or if feedback mechan-
isms compensate for gene dosage, or if, at this adult age, the
HSA21 genes are silenced or expression is reduced from the
mouse orthologs to maintain disomic levels. Protein expres-
sion in the embryonal stem (ES) cell line used in the produc-
tion of the Tc1 was analyzed by mass spectrometry (33). Of
the few HSA21 proteins detected in that work, only CCT8
was analyzed here, and it was not overexpressed in either ex-
periment.
Another Tc1 study compared levels of DYRK1A, and total
and phosphorylated forms of GSK3B, AKT and Tau in the
cortex and hippocampus of 2-month and 20-month-old mice
(15). Specific to 20-month-old Tc1 mice relative to age-
matched controls, levels of pGSK3B-Ser9, pAKT-Ser473
and pTau-Thr212 were elevated in both the cortex and hippo-
campus. None of these abnormalities is observed in the 7- to
8-month-old Tc1 mice; rather mice at this age have elevated
levels of pGSK3B-Tyr216 in the cortex and total GSK3B in
the cortex and hippocampus (and cerebellum). Because phos-
phorylation of Try-216 increases GSK3B activity and phos-
phorylation of Ser-9 inhibits it (34), these data suggest that,
at this interim age, kinase activity of GSK3B is enhanced in
Tc1, at least in the cortex. Also in contrast to 20-month-old
Tc1 mice, 7- to 8-month-old Tc1 have increased the levels of
the regulatory subunit of the phosphatase PPA2 in the hippo-
campus and increased the levels of total Tau, but not pTau-
Thr212, in the cortex and hippocampus. Together, these age
comparisons suggest that changes occurring in the Tc1 through-
out adult life are not necessarily a simple transition from
the levels observed at 2 months of age to those seen at 20
months, but rather may involve a complex program of changes
in regulatory mechanisms. This also suggests that developing
pharmacotherapies to modulate abnormalities that may be re-
sponsible for cognitive deficits seen in DS will require
careful studies of age-dependence and time courses.
Characterizing the response to trisomy of .70 non-HSA21
proteins has revealed many novel perturbations and consider-
able complexity in the pathway associations of the abnormal-
ities. This is true both in the proteins showing abnormal levels
and in those showing altered correlations in levels. The Tc1
mice are functionally trisomic for 120 protein-coding
genes. For the majority of these proteins, there is little or no
functional information beyond sequence similarities to gene
family members or protein functional domains or motifs
(9,35). Furthermore, because of the lack of quality antibodies,
there is also little information on which of these proteins is
overexpressed in trisomy (36). It is, therefore, difficult to
speculate meaningfully regarding which specific HSA21
Figure 4. Variation in IEG protein levels. Levels of non-HSA21 proteins (A)
CFOS, (B) pCFOS and (C) ARC, determined by RPA, are shown in individual
euploid controls (white bars) and Tc1 (black bars) in cortex and hippocampus.
Relative to euploid controls, average levels of all three proteins are elevated
in the hippocampus but not the cortex of Tc1.
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proteins are causing or contributing to the alterations seen in
levels of non-HSA21 proteins. This point is discussed in
detail in (35). In Supplementary Material, Table S5, we list
10 HSA21 genes uniquely trisomic in the Tc1 that have
been shown to function in learning and memory, neurite out-
growth, neuroinflammation, protein stability and/or gene tran-
scription. Each of these are processes that could underlie
non-HSA21 protein abnormalities in the Tc1. In addition to
such speculation, it is, however, both practical and more
important to understand how the observed perturbations con-
tribute to learning and memory deficits and behavioral abnor-
malities. There are several examples of potentially informative
consequences.
(i) ERBB4 is a tyrosine kinase receptor that binds to and
mediates signaling from neuregulin 1 (NRG1) (22).
ERBB4 has not been studied in the context of DS, but
a number of observations make its elevated expression
in both the cortex and hippocampus of Tc1 mice worth
further consideration. Expression of ERBB4 in the adult
brain is largely confined to GABAergic interneurons
(37). Knockout of ERBB4, specifically in parvalbumin-
expressing interneurons, resulted in abnormalities of LTP
and impaired performance in context fear conditioning
(CFC) (38). A mouse model of Angelman syndrome
showed increased levels of phosphorylated ERBB4, defi-
cits in CFC and abnormalities in LTP, all of which were
rescued by inhibition of ERBB4 (39). Thus, altered
levels of ERBB4 result in abnormalities that are consistent
with features seen in several mouse models of DS, includ-
ing the Tc1. Levels of ERBB4 are also elevated in brains
from patients with AD, particularly in hippocampal and
basal forebrain neurons, and similar increases are seen in
the hippocampus and cortex from the APP/PSEN1 double-
transgenic mouse model of AD (40). As in the Tc1 mice, it
is not known whether these increases in ERBB4 protein
levels contribute to, or are a consequence of, the disease
process, but analysis of ERBB4 expression in DS and in
AD in DS is warranted. ERBB4 is proteolytically pro-
cessed by g-secretase and the intracellular domain has
been shown to activate transcription of a number of
genes, among them the HSA21 gene ITSN1 (17). There-
fore, elevated ERBB4 may be contributing to the elevated
levels in the Tc1 of the ITSN1 protein in spite of the lack
of trisomy of the ITSN1 gene. Lastly, ERBB4 activity reg-
ulates dendritic spine formation (22). This adds a
non-HSA21 protein to the list of HSA21 proteins (APP,
TIAM1, ITSN1, PCP4, RCAN1 and DSCAM) that have
been associated with spine abnormalities when overex-
pressed and that are candidates for such abnormalities in
DS (35). In summary, while the HSA21-related molecular
mechanisms leading to elevated ERBB4 expression in Tc1
mice are not known, the consequences of perturbed
ERBB4 levels observed in other disease models suggest
that there are multiple mechanisms by which the Tc1
phenotype could be influenced and this requires investiga-
tion in full trisomy.
(ii) The AMP-activated Protein Kinase, AMPK, is a master
regulator of cellular energy homeostasis. AMPK is acti-
vated by phosphorylation of the catalytic subunit,
AMPKA. Low cellular ratios of AMP:ATP result in
increased levels of phosphorylated AMPKA which then
functions to increase ATP production and repress pro-
cesses, such as protein translation, that consume high
levels of ATP (reviewed in 41). The levels of total
AMPKA are elevated specifically in Tc1 hippocampus,
and while levels of pAMPKA could not be measured
because of the lack of an appropriately specific antibody,
this suggests altered AMPK activity or regulation. Acti-
vation of AMPK in hippocampal slices has been shown
to decrease mTOR signaling by decreasing phosphoryl-
ation levels of P70S6 and S6 (42). Increased pAMPKA
also inhibited maintenance of late-LTP, a process requir-
ing mTOR signaling and protein synthesis. The mTOR
pathway is perturbed in Tc1 mice because, although
levels of phosphorylated forms are not altered, the
levels of total P70S6 are increased in the cortex and
hippocampus, and RAPTOR is increased in the hippo-
campus, suggesting decreased ratios of active to inactive
mTOR components. Oxidative stress activates AMPK
(43), a possible link to perturbations in DS where
increased levels of reactive oxygen species are well docu-
mented. It is also of interest that levels of pAMPKA are
decreased in AD brains (41).
(iii) SOD1 protein levels are elevated, due to trisomy, in all
three brain regions of Tc1 mice. The levels of the IEG
Figure 5. Correlations among HSA21 proteins ITSN1 and DYRK1A and components of the MAP kinase signaling cascade. (A) cortex; (B and C) hippocampus.
Correlations with r. 0.8, with linear scatter plots and P , 0.05 (Spearman correlation analysis) were considered significant and are shown. Heavy solid lines,
correlations seen in controls and Tc1; thin solid lines, correlations seen only in controls; dashed lines, correlations seen only in Tc1. All correlations are positive.
Grey circles, HSA21 proteins; open circles, non-HSA21 proteins. Phosphorylation-dependent and -independent forms are shown separately. Asterisk indicates
average levels are increased in Tc1 with respect to controls.
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proteins ARC, cFOS and pCFOS are also elevated specif-
ically in Tc1 hippocampus. The network in Figure 7A
shows correlations specific to Tc1 between SOD1 and
IEG proteins through nNOS and Tau. A functional/regu-
latory relationship between SOD1 and IEGs was demon-
strated in a transgenic mouse overexpressing SOD1.
Kainate treatment induced cFOS expression (neither
ARC nor pCFOS were measured) in both controls and
transgenic mice but in the presence of elevated SOD1
protein, elevated cFOS levels persisted longer (.24 h
compared with ,14 h in control mice) (44). This indi-
cates that elevated levels of SOD1 alone can lead to
altered regulation of the production or half-life of IEG
proteins. Other reports have shown increased expression
of cFOS and EGR1 in response to oxidative stress
(45,46) and suggested that this induction is protective
(47). If elevated levels of IEG proteins in Tc1 mice are
a protective response to elevated levels of oxidative
stress, they may be a compensatory response in Tc1
(and DS) and not an abnormality that would be beneficial
to alter directly with pharmacotherapies.
(iv) In contrast to observations in human DS lymphoblastoid
cell lines (48), no correlations were observed in Tc1 brain
regions between the levels of DYRK1A and BDNF.
Indeed, BDNF levels were decreased and only in Tc1
cortex.
In prior work, we reported a similar analysis of protein expres-
sion in Ts65Dn mice (13). The Ts65Dn mice were similar in
age (4.4 to 7.8 months) to the Tc1 analyzed here, and
methods of tissue collection, protein lysate preparation and
reverse phase protein array analysis were identical. The meth-
odological issues are important, because they will affect ex-
perimental observations. In particular, heat stabilization
preserves protein profiles while use of anesthetics, perfusion
and the time frame of tissue dissection will each cause their
own changes. In addition, RPA is more sensitive and accurate
than standard quantitative western blot procedures. Figure 8
illustrates the regions of HSA21 and the orthologous region
of mouse chromosome 16 that are trisomic in the Tc1 and
Ts65Dn, respectively. In Figure 9, proteins with altered
levels in one or both models are compared for the three
brain regions (percent changes for each protein and brain
region in Ts65Dn are provided in (13) and in Supplementary
Material, Table S4). The Tc1 and Ts65Dn mice differ in
strain background (C57BL6/J X 129S8 and C57BL6/JEi X
C3H, respectively) and in trisomic gene content; both of
these features can contribute to differences in protein expres-
sion levels. The Ts65Dn mice are trisomic for orthologs of 88
of the 161 HSA21 classical protein coding genes and 50 of
these are also trisomic in the Tc1 (Fig. 8; see Supplementary
Material, Table S6a for the complete list of HSA21 RefSeq
genes and their trisomic status in the Tc1 and Ts65Dn).
Ts65Dn-specific trisomic HSA21 genes include APP and
genes within the region spanning just distal to HUNK through
RUNX1. This region contains 37 protein coding genes, includ-
ing synaptojanin 1, the OLIG1 and OLIG2 genes, the interferon
receptor cluster, and RCAN1. Tc1-specific trisomic genes
include 15 that are proximal to APP, including C21ORF34
that is the host gene for three microRNA genes, the 19 genes
mapping within the MMU17 orthologous region and, with the
exception of TRPM2, COL18A1 and PCBP3, 38 within the
MMU10 orthologous region. The Ts65Dn, in addition, is triso-
mic for a centromere-proximal segment of mouse chromosome
17 that is not orthologous to HSA21 (Fig. 8). This has recently
been shown to include 50 genes (49,50), including paralogs of
several HSA21 protein-coding genes, TIAM2, SYNJ2, TCP10A,
TCP10B and PDE10a (see Supplementary Material, Table S6B
for the complete list). Consistent with differences in trisomic
gene content, there are striking differences in both HSA21
and non-HSA21 protein perturbations in these two partial
trisomy models. One obvious difference is that abnormalities
Figure 6. Correlations involving the HSA21 protein TIAM1 in hippocampus. (A) With subunits of the NMDA receptor and the HSA21 protein APP, (B) with
GSK3B and HSA21 proteins RCAN1 and DYRK1A. Correlations between protein levels were determined by Spearman correlation analysis; only correlations
with r . 0.8, with linear scatter plots and P , 0.05 are shown. Heavy solid lines, correlations seen in controls and Tc1; thin solid lines, correlations seen only in
controls; dashed lines, correlations seen only in Tc1. Grey circles, HSA21 proteins; open circles, non-HSA21 proteins. Phosphorylation-dependent and
-independent forms are shown separately; pGSK3B_T, pTyr216; pGSK3B_S, pSer9. N, negative correlation. Asterisk indicates average protein levels are
increased in Tc1 with respect to controls.
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in the Tc1 mice are more consistent among brain regions;
indeed, of 22 proteins with elevated expression, 15 are elevated
in all regions tested. In contrast, in the Ts65Dn mice, brain
region-specific abnormalities are more common; only 4 of 22
proteins are increased in all brain regions tested. This is true
even for HSA21 proteins, e.g. in the Ts65Dn, TIAM1 is not ele-
vated in the hippocampus. Little is known about the specificities
of TIAM2 versus TIAM1 (51), but it cannot be excluded that
TIAM2 gene dosage in the Ts65Dn modulates TIAM1 gene ex-
pression to produce effects not present in the Tc1 mice.
Notable abnormalities unique to the Tc1 mice are elevated
levels of the IEG proteins, ARC, CFOS and pCFOS. That
IEG proteins are not altered in the Ts65Dn was unexpected
based on recent observations of decreased levels of mRNAs
for ARC and CFOS in Ts65Dn relative to controls after expos-
ure to the Morris Water Maze, and their normalization by
treatment with a GABAAa5 antagonist that also rescued
learning and memory impairments (19). One interpretation is
that mRNA levels in the Ts65Dn are depressed as a feedback
mechanism to maintain normal protein levels. Another possi-
bility is that altered IEG expression is age related, decreased
in 3-month-old mice and normal in the slightly older mice
used here. Other Tc1-specific abnormalities include elevated
ERBB4 in the cortex and hippocampus. This is of interest
because ERBB4 expression is restricted to GABAergic inter-
neurons, and, although not studied in the Tc1, GABAergic
transmission is abnormal in the Ts65Dn. The complete
picture is complicated to interpret, however, because in con-
trast to the Tc1, ERBB4 is not elevated in the Ts65Dn (at least
at the age studied here), suggesting that abnormal ERBB4 ex-
pression may contribute to phenotype in the Tc1 but not in
the Ts65Dn.
Perturbations unique to the Ts65Dn mice include decreased
levels of CDK5 and p35/25 in the hippocampus, and perturba-
tions of levels of more phosphorylated proteins, including
decreased levels of pMTOR and pMEK1/2 and increased
levels of pPKCG and pRSK. Interestingly, total ubiquitin
levels are uniquely decreased in Ts65Dn hippocampus.
The Tc1 and Ts65Dn models also differ in patterns of cor-
related protein levels. In the hippocampus, many correlations
among subunits of the NMDAR are preserved in the Tc1
mice (Fig. 6a). However, only those for NR2A-pNR2B and
pNR2B-NR2B were also preserved in the Ts65Dn (13). In add-
ition, the Ts65Dn showed none of the correlations between
TIAM1 isoforms and NMDAR subunits that are gained in the
Tc1. These differences may be related to the increased levels
of APP unique to the Ts65Dn and the increased levels of
TIAM1 unique to the hippocampus in the Tc1. In the MAP
kinase pathway networks, in the hippocampus fewer correla-
tions are lost in the Tc1 than in the Ts65Dn, while in cortex,
most correlations are equally stable to trisomy effects.
Overall, protein abnormalities in these partial trisomy
models of DS are complex and multi-faceted. As has also
commonly been done with DS and DS model RNA expression
studies, entire brain regions were analyzed here. Each brain
region of course contains many different cell types, excitatory
and inhibitory neurons, astrocytes, etc., and the protein profiles
observed are therefore composites of those present in the spe-
cific cell types. For each brain region, they are also composites
of the profiles that exist in subregions, e.g. for the hippocam-
pus, they are composites of those in the CA1, CA3 and dentate
gyrus. Future studies could include generation of protein pro-
files from such subregions, which might then provide insight
into the specific molecular correlates of, for example, abnor-
malities in LTP.
Aside from differences in strain backgrounds, doubtless, in
both the Tc1 and the Ts65Dn, many of the observed perturba-
tions are direct consequences of increased expression of triso-
mic genes or are part of resulting cascade reactions. However,
some of the abnormalities are likely to be compensatory
Figure 7. Correlation involving Immediate Early Gene (IEG) proteins in (A) hippocampus and (B) cortex. Correlations between protein levels were determined
by Spearman correlation analysis; only correlations with r. 0.8, with linear scatter plots and P, 0.05 are shown. Heavy solid lines, correlations seen in controls
and Tc1; thin solid lines, correlations seen only in controls; dashed lines, correlations seen only in Tc1. Dark grey circles, IEG proteins; light grey circles, HSA21
proteins; open circles, non-IEG, non-HSA21 proteins. Phosphorylation-dependent and -independent forms are shown separately. N, negative correlation. Asterisk
indicates average protein levels are increased in Tc1 with respect to controls.
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responses to the primary perturbations, involving feedback
control mechanisms. Furthermore, some perturbations will
be influenced, positively and negatively, by functional interac-
tions among HSA21 genes, and the number and identity of
such interactions will also differ with trisomic gene content.
Thus, relative to the TS65Dn, Tc1-specific features of the
protein profiles are a complex result of trisomy of 121
HSA21 genes plus the lack of trisomy of the 38 Ts65Dn-
specific protein-coding genes. Importantly, the differences in
protein patterns between the Tc1 and Ts65Dn mice clearly
preclude reliable inferences regarding what perturbations
exist in a full trisomy, i.e. in the DS brain or in the brain in
DS with AD. This limitation in knowledge must be considered
in making decisions to move to clinical trials based on drug
responses observed in a partial trisomy HSA21 mouse
model, such as the Ts65Dn. Indeed, the Tc1 mice show
protein abnormalities potentially relevant to oxidative stress,
and NMDA and GABA receptor signaling. Drugs targeting
each of these processes have been or are being used in clinical
trials with people with DS (52–54). So far, antioxidants and
the NMDA receptor antagonist, memantine, have shown no
or very limited benefit. Rationales for these failures have
included the age of participants, duration of the trial and/or
number of participants. Data from the Tc1 mice, and their sig-
nificant differences from those in the Ts65Dn mice that were
used in pre-clinical evaluation of antioxidant, memantine
and GABAA antagonist responses, indicate that a plausible
cause of the failure of clinical trials is the quite different mo-
lecular basis of the phenotype in DS and consequent quite dif-
ferent drug responses.
Figure 9. Comparison of protein expression abnormalities in Tc1 and Ts65Dn.
All proteins with an average expression level significantly different from cor-
responding controls in at least one brain region of at least one mouse model are
listed at right. Proteins are grouped by general category. Yellow, increased;
blue, decreased; black, unchanged; grey, not measured. % difference from re-
spective controls are provided in Table 1 for Tc1 and in Supplementary Material,
Table S4 for Ts65Dn (13). Cr, cortex; HP, hippocampus; CB, cerebellum.
Figure 8. Chromosome 21 long-arm and orthologous mouse chromosome 16
region trisomic in the Tc1 and the Ts65Dn mice, respectively. D1, segment of
HSA21 present in Tc1 and absent in Ts65Dn; grey-shaded D2, D3, internal
deletions in the Tc1 HSA21 chromosome. R1, region of mouse chromosome
17 uniquely trisomic in the Ts65Dn; R2, HSA21 orthologous region of
mouse chromosome 16 trisomic in the Ts65Dn; R3, HSA21 segment uniquely
trisomic in the Tc1. RefSeqP, number of HSA21 annotated classical protein
coding genes trisomic in the Tc1, and the number of mouse orthologs trisomic
in the Ts65Dn (9). The complete list of protein-coding genes trisomic in
regions D1–D3 and R1–R3 and additional details of Tc1 gene-specific
partial deletions and duplications are provided in Supplementary Material,
Table S6.
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MATERIALS AND METHODS
Mice
Mice were bred at the University College London Institute of
Neurology, London, UK. Mice were housed in controlled con-
ditions in accordance with guidance issued by the Medical Re-
search Council in Responsibility in the Use of Animals for
Medical Research (1993) and all experiments were carried
out under License from the UK Home Office and with Local
Ethical Review panel approval. Tc1 mice are maintained by
mating Tc1 females to 129S8 X C57BL/6 F1 males and
typed using DNA from tail tips as described previously (10).
Littermates were housed in the same cage. Male mice, litter-
mates, 7 controls and 7 trisomy, aged 7 months (Supplemen-
tary Material, Table S1), were sacrificed by cervical
dislocation without anesthetic and the brain quickly
removed, frozen in liquid nitrogen, and stored at 2808C
until use. All mice were naı¨ve and were sacrificed between
noon and 2 PM to maintain a consistent circadian time
frame. Optimal preservation of protein profiles precludes the
use of anesthetic and perfusion.
Tissue processing and preparation of protein lysates
To optimally preserve protein profiles, including phosphoryl-
ation, prior to lysate preparation, tissues were heat stabilized
in the Stabilizor T1 (Denator, AB, Gothernburg, Sweden) as
described previously (13,55,56). Briefly, tissues were
removed from 808C and, without thawing, immediately
placed in the sample cassette and inserted into the Stabilizor
T1 where they were exposed to rapid heating to 958C under
vacuum. This process has been shown to prevent normal post-
mortem proteolytic events and alterations in posttranslational
modification that occur in particularly in response to the use
of anesthetics and during perfusion, but also during prepar-
ation of lysates when tissues are exposed to thawing (55,56).
After stabilization, brains minus cerebellum were dissected
into the hippocampus and cortex. Brain stem was removed
from the cerebellum; for the cortex, the entire region remain-
ing after the removal of hippocampus and striatum was used.
The cortex, hippocampus and cerebellum tissue samples were
weighed (Supplementary Material, Table S1) and whole tissue
lysates were placed in 10 volumes of Iso Electric Focusing
(IEF) buffer [8 M urea, 4% 3-[(3-cholamidopropyl)dimethy-
lammonio]-1-propanesulfonate (CHAPS), 50 mM Tris] and
homogenized by sonication (three bursts of 5 s duration in
Branson Sonic Power Co., Danbury, CT, USA), followed by
brief centrifugation to remove debris. Protein concentrations,
determined using the 660 nM Protein Assay kit (Thermo Scien-
tific, Rockfold, IL, USA), were within the range of 9–11 mg/ml
for all samples. Information for each mouse on age, littermates
and weights of individual brain regions is provided in Supple-
mentary Material, Table S1.
Western blots
Twenty micrograms of protein lysates per lane were separated
at 170 V, constant voltage for 21
2
h on sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS–PAGE) gels (8, 10
or 12% depending upon size the proteins to be detected).
Following electrophoresis, proteins were transferred to polyvi-
nylidene difluoride (PVDF) membranes at 250 mA constant
current for 11
2
h. Membranes were blocked with 5% (w/v)
non-fat dry milk in TBST (Tris-buffered saline, 0.1% Tween
20), followed by overnight incubation at 48C with primary
antibody. Detection of bound primary antibodies was per-
formed with alkaline-phosphatase-conjugated goat anti-rabbit
(Invitrogen, Camarillo, CA, USA) or goat anti-mouse (Cell
Signaling Technology, Danvers, MA, USA) secondary anti-
bodies. Signals were detected with CDP-Star Chemilumines-
cence reagent; imaging and quantitation were carried out
using the Diana III CCD camera and Aida software
(Raytest, Inc., Germany). All membranes were stripped in
0.2 M glycine pH 2.5/0.05% Tween 20, at 708C for 20 min,
and re-probed with actin antibody (Sigma, Saint Louis,
MO, USA) for normalization. For genotype comparisons,
data were analyzed using GraphPad Prism 5 software (San
Diego, CA, USA). The unpaired Student t-test was used for
statistical evaluation and the P-value of ,0.05 was consid-
ered statistically significant.
Antibodies and validation for RPA
All antibodies were verified by western blots to cross-react
with both mouse and human proteins. To determine suitability
for use in RPA, each lot of each antibody was also verified to
produce clean band(s) of the correct size(s) in the absence of
significant background and non-specific bands, i.e. to produce
predominant band(s) of explainable size. Antibodies are listed
in Supplementary Material, Table S2 with supplier and dilution
factor. With the exception of S100B and RAGE, which identify
bands in addition to those explained by alternative splicing and
proteolytic cleavage, all antibodies listed in Supplementary Ma-
terial, Table S1 are suitable for RPA. TIAM1 was evaluated by
western blots, instead of RPA, to determine relative proportions
of splice variants and proteolytic cleavage products.
Array assembly and printing
For each sample, lysates, neat plus four serial dilutions (dilution
factor 0.8) and one buffer control, were pipetted into V-shaped
ABgene 384-well plates (Thermo Fisher Scientific, Rockford,
IL, USA). Samples were printed in quadruplicate onto
nitrocellulose-coated glass slides (Path or SuperNova slides,
Grace Bio-Labs, Inc., Bend, OR, USA), using an Aushon Bio-
Systems 2470 Arrayer (Aushon BioSystems, Billerica, MA,
USA) with 185 mm pins and a single touch. Arrays were pro-
duced in four print runs. The first run included samples from
the cortex, hippocampus and cerebellum, while runs 2–4
included either the cortex or hippocampus only. Eight milli-
grams of starting tissue is sufficient to spot 100 slides.
Slides were stored at 48C until use.
Antibody detection and array staining
Procedures for array screening have been described previously
(13). Briefly, slides were incubated in blocking solution (3%
BSA (Sigma-Aldrich Co, Saint Louis, MO, USA) in TBST
(Tris-buffered saline, 0.1% Tween 20) for 4 h, followed by
overnight incubation at 48C with primary antibody (antibody
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dilutions are provided in Supplementary Material, Table S1).
Detection of bound primary antibodies was performed by in-
cubation for 90 min at room temperature with Fluorescence
Alexa Fluor 555 goat anti-mouse or anti rabbit or rabbit anti-
goat (Invitrogen, Camarillo, CA, USA) secondary antibodies
(1:2000). Slides were washed with TBST three times for
5 min and dried for 20 min at 308C. All the steps including
and following the incubation with secondary antibody were
performed in the dark. For normalization purposes, total
protein in each spot was determined by staining two to three
non-sequential slides from each print run with SyproRuby
reagent (Invitrogen, Camarillo, CA, USA) following the man-
ufacturer’s protocol.
Slide scanning, image analysis, quantification,
normalization and review of data quality
Slides screened with antibodies or stained with SyproRuby
were scanned on a GenePix 4000B array slide scanner (Axon
Instruments, Union City, CA, USA) using GenePix Pro 4.0 soft-
ware. The intensity of each spot was quantified using the Sca-
nArray Express software (PerkinElmer, Inc., Boston, MA,
USA). Antibody signal for each spot was normalized to the cor-
responding SyproRuby signal. Details of quantification and
review of data quality and reproducibility were as described
previously (13).
Statistical analysis
After exclusion of technical outliers, all SyproRuby-
normalized protein values were included in the statistical ana-
lyses; data were transformed to a natural log scale. Mean dif-
ferences in protein levels between genotypes (trisomy versus
control, reported as a ratio and percent of control) were
assessed using a hierarchical three-level mixed effects model
to account for the possible correlations and variabilities
among replicates and dilution levels within each mouse. To
carry out a correlation analysis, data were reduced to one ob-
servation per mouse. Protein values for each brain region of
each individual of each genotype were used to compute Spear-
man correlation coefficients. Graphs for data from protein
pairs with correlation coefficients .0.8 with P, 0.05 were
inspected and correlations with artifactually high r values
(i.e. non-linear relationships) were eliminated. All data ana-
lyses were carried out using SASw (version 9.2, SAS Institute,
Inc., Cary, NC, USA). A two-tailed P-value of ,0.05 was
considered for overall statistical significance across the entir-
ety of the hypotheses tests; Bonferroni correction and false
discovery rate were applied to correct P-values from pairwise
multiple tests. Supplementary Material, Table S3 shows all
significant correlations (r . 0.8; P , 0.05) for all three brain
regions. Correlation networks were created using JAVA
JUNG2 software.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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